Purchase Order VA580W15967
Award Date 2/16/11
Potential Completion Date 3/16/11
Potential Value $4.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Scottsdale, AZ 85257, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of May 8, 2011 and was awarded through Regenesis Biomedical's existing GSA Schedule...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of January 20, 2011. Regenesis Biomedical has provided the Provant Therapy System and related rental...
- This federal contract award, valued at $4,820.98, was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical, to VA medical facilities. The contract was awarded as a purchase order under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A...
- This federal contract award, valued at $7,145.55, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. This contract appears to be a purchase order under Regenesis Biomedical's existing GSA Schedule 65-II-A contract...
- This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company, for the provision of the Provant Therapy System, a noninvasive regenerative medicine product. The $4,820.98 firm-fixed-price purchase order contract was awarded on January 10, 2011, with a completion date of February 10, 2011. The contract was awarded under Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A for...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $3,645.14 firm fixed-price contract is for the provision of the Provant Therapy System, a noninvasive regenerative medicine product, and related rental services. The contract was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. No set-aside designation was used. The contract...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The contract does not utilize any set-aside designations. Based on the information provided, Regenesis Biomedical acts as the prime contractor and does not subcontract...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 firm-fixed-price purchase order is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of January 27, 2011. Regenesis Biomedical is the prime...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The $4,820.98 firm-fixed-price purchase order is for the company's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was issued under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies,...